COPERNICUS Design and Subcutaneous Amivantamab in First-Line Care

Elizabeth Dennis, MSN, APRN, FNP-C, describes what distinguishes the COPERNICUS study from the MARIPOSA trial in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer: a focus on treatment implementation, not only efficacy. She explains that COPERNICUS evaluates subcutaneous amivantamab-based regimens, including first-line amivantamab plus lazertinib and second-line amivantamab plus chemotherapy, in a more pragmatic clinical setting and assesses safety and adherence to prophylactic strategies designed to reduce dermatologic toxicities, venous thromboembolism, and administration-related reactions. Ms. Dennis considers this focus important because many patients have comorbidities and real-world challenges that traditional trials may not fully represent. She cautions that COPERNICUS is a single-arm study without a randomized comparator and with early follow-up, which limits direct comparisons and long-term conclusions. She views subcutaneous amivantamab as an important first-line addition that may shorten administration time and reduce administration-related reactions. Ms. Dennis stresses that it expands, rather than replaces, frontline options and supports individualized decisions.